The provision of prostate cancer patient information leaflets on an electronic tablet: A further step to paperless health-care provision
- PMID: 35711488
- PMCID: PMC9197007
- DOI: 10.4103/UA.UA_174_20
The provision of prostate cancer patient information leaflets on an electronic tablet: A further step to paperless health-care provision
Abstract
Introduction: The provision of patient information leaflets (PILs) for cancer treatment options is primarily via a paper format. PILs can now be provided on an electronic tablet with the added benefits of providing audio-visual information.
Materials and methods: Between February 2017 and August 2019, 112 patients with newly diagnosed prostate cancer (PCa) were enrolled into our prospective cohort study. The control group (n = 56) were all given PILs on a paper as the standard of care (SoC). The intervention (tablet) group (n = 56) were given the same paper PILs as that of the control group plus an electronic tablet computer with an application containing all SoC paper PILs in an electronic format and supplementary videos detailing treatments. Both groups were asked to complete a validated questionnaire (Telemedicine, Satisfaction and Usefulness questionnaire) with regard to satisfaction with care, provided information, and tablet usage.
Results: The response rate for our study was 78/112 (70%). The control and tablet groups were highly satisfied with their care (91%-100% agreed or strongly agreed) and with the information they received (80%-100% agreed or strongly agreed). In the tablet group, 41/46 (89%) reported its utilization. Of those 41, 38 (92%) considered the tablet easy to use and 13 (32%) reported a preference for the paper format.
Conclusions: The provision of electronic PILs in PCa treatment is an innovative method of providing oncological care, with positive feedback from our patients. With further development as a mobile application, electronic PILs may allow a more environmentally and fiscally advantageous method of providing PCa care.
Keywords: Electronic tablet; environment; patient information leaflets; telemedicine.
Copyright: © 2022 Urology Annals.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
Are Electronic and Paper Questionnaires Equivalent to Assess Patients with Overactive Bladder?J Urol. 2018 Aug;200(2):369-374. doi: 10.1016/j.juro.2018.03.117. Epub 2018 Mar 30. J Urol. 2018. PMID: 29605443
-
Patient information leaflet in the era of digitalisation: a cross-sectional study on patients' attitudes and practices.Ir J Med Sci. 2024 Apr;193(2):777-782. doi: 10.1007/s11845-023-03515-2. Epub 2023 Sep 7. Ir J Med Sci. 2024. PMID: 37676583
-
Patient reported outcomes and recruitment rates following the introduction of principled patient information leaflets (PrinciPILs): Protocol for a meta-analysis.NIHR Open Res. 2023 May 26;3:29. doi: 10.3310/nihropenres.13420.1. eCollection 2023. NIHR Open Res. 2023. PMID: 39139272 Free PMC article.
-
Recommendations for developing accessible patient information leaflets for clinical trials to address English language literacy as a barrier to research participation.Trials. 2024 Sep 27;25(1):624. doi: 10.1186/s13063-024-08471-5. Trials. 2024. PMID: 39334243 Free PMC article. Review.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
References
-
- McPherson CJ, Higginson IJ, Hearn J. Effective methods of giving information in cancer:A systematic literature review of randomized controlled trials. J Public Health Med. 2001;23:227–34. - PubMed
-
- Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415–24. - PubMed
-
- Shah TT, Peters M, Eldred-Evans D, Miah S, Yap T, Faure-Walker NA, et al. Early-medium-term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry. Eur Urol. 2019;76:98–105. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources